Loading...
NPI 1316012909 · Edison, NJ · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Rnj Services, Inc is a clinical medical laboratory provider located in Edison, New Jersey. This profile covers 194 Medicare and 106 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Rnj Services, Inc |
| Address | 35-37 Progress St Ste B6 |
| City | Edison |
| State | NJ |
| ZIP | 08820 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | November 21, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $7.5M |
| Medicare | $5.8M |
Payer mix and scale: RNJ SERVICES, INC reports measurable activity in both Medicare and Medicaid, with total Medicare revenue of $5.8M and total Medicaid revenue of $7.5M, making Medicaid the larger single payer by reported dollars. The presence of sizable revenues on both programs indicates the lab operates across payer types rather than as a single-payer specialist.
Medicare revenue concentration: The provider’s Medicare billing is concentrated in a small set of high-revenue molecular/infectious-disease codes — the top three Medicare codes account for 47.4% of Medicare revenue. Notable contributors include 87798 ($1.2M, 25.3% of Medicare revenue; ranks #53 of 1319 providers nationally, 96th percentile; typical, unremarkable volume for this code), 87150 ($761.7K, 15.6% of Medicare revenue; ranks #18 of 190 providers nationally, 91th percentile; typical, unremarkable volume for this code), and 87481 ($323.7K, 6.6% of Medicare revenue; ranks #49 of 1117 providers nationally, 96th percentile; typical, unremarkable volume for this code), which together drive nearly half of Medicare revenue and point to a molecular/infectious testing focus on that payer.
Medicaid revenue concentration and service mix: Medicaid billing is even more concentrated — the top three Medicaid codes account for 81.8% of Medicaid revenue — and is dominated by drug-testing services. The Medicaid top codes are G0480 ($2.9M, 39.3% of Medicaid revenue; ranks #11 of 110 providers in-state, 91th percentile; typical, unremarkable volume for this code) and 80307 ($2.6M, 36.3% of Medicaid revenue; ranks #17 of 151 providers in-state, 89th percentile; typical, unremarkable volume for this code), with U0004 ($452.3K, 6.2% of Medicaid revenue; ranks #28 of 67 providers in-state, 59th percentile; typical, unremarkable volume for this code) completing the concentrated Medicaid mix.
Business and operational profile: The code mix (Medicare molecular/infectious codes such as 87798, 87150, 87481 and Medicaid drug-testing codes like G0480 and 80307) describes a clinical laboratory that performs high-volume nucleic acid/probe testing alongside large-scale drug screening. Heavy counts for travel and specimen-collection codes — P9603 (85.2K claims, $85.2K revenue), P9604 (12.9K claims, $141.7K revenue) and G0471 (25.6K claims, $256.2K revenue) — further indicate substantial specimen collection logistics and relationships with homebound or SNF/HHA populations rather than a purely clinic‑based draw operation.
Competitive standing on Medicare: RNJ shows strong national placement for several routine and specialty tests but is described as typical for many molecular codes; for example, 87798 is $1.2M and ranks #53 of 1319 nationally (96th percentile; typical, unremarkable volume for this code) while 87150 ranks #18 of 190 nationally (91th percentile; typical, unremarkable volume for this code). The provider also posts unusually high national volume for several routine chemistry and hematology tests (for example, 85025 is reported as notably above typical national volume and ranks #117 of 32833 providers nationally, 100th percentile).
Competitive standing in-state for Medicaid: Within New Jersey RNJ is a high-ranking in-state participant for drug-testing codes but is still characterized in the source data as having "typical, unremarkable volume" for those lines; G0480 ranks #11 of 110 in-state (91th percentile) and 80307 ranks #17 of 151 in-state (89th percentile). The large Medicaid dollar share tied to those two codes ($2.9M and $2.6M respectively) marks RNJ as a significant state-level supplier of definitive and presumptive drug testing.
Statistical outliers and high-volume signals: The profile includes multiple tests flagged as "notably above typical national volume" or at the top percentiles for claim counts, beyond the molecular work — examples include 85025 (CBC) characterized as notably above typical national volume (100th percentile) and panel tests such as 80053 and 80061 appearing at very high national percentiles (99th–100th percentile). These labels suggest the lab operates at volumes for some common panels and hematology tests that exceed typical peer activity, in addition to its molecular and drug-testing lines.
Tenure and continuity: The provider’s NPI was enumerated on 2006-11-21 (~20 years ago), indicating long-standing enrollment and an established operating history in clinical laboratory services. That tenure, combined with steady high claim counts across collection and testing codes, supports an interpretation of sustained operations rather than a short-term or newly established testing practice.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
194 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 36,390 | $30 | $1.2M |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 22,400 | $30 | $761.7K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 9,520 | $30 | $323.7K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 10,030 | $30 | $290.8K |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 25,620 | $10 | $256.2K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 15,720 | $20 | $251.6K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 20,870 | $10 | $208.7K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 14,800 | $10 | $192.3K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 22,300 | $10 | $178.4K |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 12,880 | $10 | $141.7K |
Showing 1–10 of 194
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 194 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
194 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0471 | 3 | 10 | 25,620 | $10 | $699.5K |
| 87506 | 9 | 10 | 110 | $260 | $506.1K |
| 87798 | 4 | 40 | 1,760 | $30 | $284.3K |
| P9603 | 3 | 10 | 11,620 | $1 | $245.2K |
| 87150 | 1 | 10 | 430 | $30 | $175.3K |
| 86769 | 9 | 20 | 100 | $40 | $140.5K |
| U0004 | 9 | 20 | 360 | $70 | $116.2K |
| 86480 | 6 | 20 | 50 | $60 | $110.8K |
| U0003 | 40 | 80 | 110 | $70 | $101.7K |
| 86235 | 19 | 40 | 160 | $20 | $95.2K |
Showing 1–10 of 194
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
106 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 32,430 | $90 | $2.9M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 52,610 | $50 | $2.6M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 7,800 | $60 | $452.3K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 4,050 | $50 | $202.6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 5,880 | $20 | $105.8K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 11,270 | $10 | $101.4K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 2,080 | $40 | $91.4K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 18,160 | $10 | $90.8K |
| 86803 | Qualitative or Semiquantitative Immunoassays; Hepatitis C antibody | 4,870 | $20 | $82.8K |
| 86696 | The lab analyst performs an immunoassay to evaluate the patient’s serum or cerebrospinal fluid, CSF, for antibodies to type 2 herpes simplex (HSV–2). | 3,960 | $20 | $79.3K |
Showing 1–10 of 106
How this provider's Medicaid billing volume and revenue compare to other New Jersey providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Jersey median
106 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 107 | 130 | 3,180 | $60 | $4.2M |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 33 | 40 | 590 | $20 | $1.9M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 17 | 150 | 3,680 | $30 | $1.5M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 28 | 70 | 4,800 | $50 | $1M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 11 | 110 | 1,810 | $50 | $930.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 70 | 140 | 5,590 | $20 | $823.1K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 14 | 90 | 630 | $30 | $806.2K |
| 86769 | The lab analyst performs a multiple–step immunoassay to evaluate the patient’s serum for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), which causes coronavirus disease… | 47 | 60 | 280 | $40 | $728.3K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 15 | 30 | 630 | $20 | $687.4K |
| 87799 | The lab analyst performs a test to quantify infection with an infectious agent, not otherwise specified in another code, using a nucleic acid probe technique. Use this code if you know the laboratory… | 9 | 30 | 480 | $30 | $623.6K |
Showing 1–10 of 106
Other providers in the same ZIP code as Rnj Services, Inc, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.